Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy

Rimeporide, a first-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. There is considerable overlap in the pathophysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Previtali, Stefano C., Gidaro, Teresa, Díaz-Manera, Jordi, Zambon, Alberto, Carnesecchi, Stephanie, Roux-Lombard, Pascale, Spitali, Pietro, Signorelli, Mirko, Szigyarto, Cristina Al-Khalili, Johansson, Camilla, Gray, Julian, Labolle, Delphine, Porte Thomé, Florence, Pitchforth, Jacqueline, Domingos, Joana, Muntoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482441/
https://www.ncbi.nlm.nih.gov/pubmed/32535224
http://dx.doi.org/10.1016/j.phrs.2020.104999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482441/
https://www.ncbi.nlm.nih.gov/pubmed/32535224
http://dx.doi.org/10.1016/j.phrs.2020.104999

Ejemplares similares